Microbix Biosystems (MBX) Q3 2025 earnings summary

Executive summary

• Q3 fiscal 2025 was the weakest quarter in three years, with revenue at $3.47 million, down 31% year-over-year, driven by lower sales to a Chinese distributor and a customer that canceled a significant development program.

• YTD 2025 revenue was $14.84 million, a 22% decrease from the prior year, with Antigens up 11% but QAPS down 25%.

• Customer concentration risk materialized, with the company unable to quickly backfill lost revenues.

• Despite setbacks, recurring sales remained stable year-over-year, and double-digit growth was seen in the QAPs business excluding the canceled customer.

• Management remains focused on resuming growth, expanding the customer base, and launching new products.

Financial highlights

• Revenue declined significantly due to the loss of two major clients, resulting in a net loss for the quarter; Q3 net loss was $1.64 million versus net income of $0.25 million in Q3 2024.

• Q3 gross margin was 41%, down from 54% in Q3 2024; YTD gross margin was 56%, down from 63% last year.

• Margins were negatively impacted by lower sales volumes and unfavorable product mix.

• Q3 operating expenses rose 22% year-over-year, with higher R&D, lower investment income, and no grant income.

• Cash and cash equivalents at June 30, 2025, stood at $12.1 million.

Outlook and guidance

• Management expects it will take several quarters to recover and return to previous growth trajectory.

• New customers, products, and programs are being targeted to rebuild sales, with significant impact expected in fiscal 2026.

• QUANTDx product line is expected to generate under CAD 500,000 in 2026, with long-term growth potential.

• No plans for significant cost-cutting or headcount reduction; focus remains on top-line growth.

• Management maintains a guarded outlook for the remainder of fiscal 2025, citing ongoing challenges in China.